Clonidine suppresses the opioid abstinence syndrome without clonidine-withdrawal symptoms: a blind inpatient study.
Nine hospitalized opioid-addicted patients were blindly given clonidine within 36 hours of the abrupt and blind discontinuation of methadone. All nine patients were successfully withdrawn from methadone and were asymptomatic upon discharge. Clonidine-treated patients had significantly fewer symptoms than a comparable group of opioid addicts abruptly withdrawn from methadone. No exacerbation of symptomatology developed after the cessation of clonidine. The clinical implications of clonidine's suppression of opioid withdrawal and the alpha-2 adrenergic mediation of the abstinence syndrome are discussed.
D000328:Adult; D003000:Clonidine / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use; D009293:Opioid-Related Disorders / Q000534:rehabilitation*; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy*
D003000:Clonidine; D008691:Methadone